Community Health Systems, Inc. Announces Second Quarter Ended June 30, 2022 Results
Community Health Systems (CYH) reported a net operating revenue of $2.934 billion for Q2 2022, a 2.4% decrease from Q2 2021. The company faced a net loss of $(326) million, or $(2.52) per share, a stark contrast to a net income of $6 million, or $0.04 per share, the previous year. Adjusted EBITDA fell to $253 million, down 44.2% year-over-year. Admissions dropped by 3.4% and adjusted admissions by 0.4%. Despite challenging operational dynamics and significant costs, the company plans strategic initiatives to address these issues and capitalize on growth opportunities.
- Projected 2022 net operating revenues expected to range from $12,200 million to $12,500 million.
- Despite current losses, the company is focusing on strategic growth initiatives to enhance market position.
- Net loss of $(326) million for Q2 2022, compared to a $6 million profit in Q2 2021.
- Adjusted EBITDA decreased by 44.2% year-over-year, indicating significant operational challenges.
- 3.4% drop in admissions and 2.5% decrease in total admissions for the first half of 2022.
The following highlights the financial and operating results for the three months ended
-
Net operating revenues totaled
.$2.93 4 billion -
Net loss attributable to
Community Health Systems, Inc. stockholders was , or$(326) million per share (diluted), compared to net income of$(2.52) , or$6 million per share (diluted), for the same period in 2021. Excluding the adjusting items as presented in the table in footnote (e) on page 14, net loss attributable to$0.04 Community Health Systems, Inc. stockholders was per share (diluted), compared to net income of$(2.52) per share (diluted) for the same period in 2021.$0.23 -
Adjusted EBITDA was
, including$253 million of pandemic relief funds.$8 million -
Net cash provided by operating activities was
for the three months ended$53 million June 30, 2022 , compared to for the three months ended$179 million June 30, 2021 . - On a same-store basis, admissions decreased 3.5 percent and adjusted admissions decreased 0.5 percent, compared with the same period in 2021.
Net operating revenues for the three months ended
Net loss attributable to
Adjusted EBITDA for the three months ended
The consolidated operating results for the three months ended
Net operating revenues for the six months ended
Net loss attributable to
Adjusted EBITDA for the six months ended
The consolidated operating results for the six months ended
The Company received pandemic relief fund payments through various federal, state and local programs of approximately
Commenting on the results,
The Company completed the divestiture of one hospital on
Information About Non-GAAP Financial Measures
This press release presents Adjusted EBITDA, a non-GAAP financial measure, which is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude loss (gain) from early extinguishment of debt, impairment and (gain) loss on sale of businesses, gain on sale of equity interests in
The non-GAAP financial measures set forth above are not measurements of financial performance under
Included on pages 15, 16, 17, 18 and 19 of this press release are tables setting forth the Company’s 2022 updated annual earnings guidance. The 2022 guidance is based on the Company’s historical operating performance, current trends and other assumptions that the Company believes are reasonable at this time as more specifically discussed below.
The Company’s headquarters are located in
Financial Highlights (a)(b) | |||||||||||||||
(In millions, except per share amounts) | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||
2022 |
2021 |
2022 |
2021 |
||||||||||||
Net operating revenues | $ | 2,934 |
|
$ | 3,007 |
$ | 6,044 |
|
$ | 6,020 |
|
||||
Net (loss) income (f) | (298 |
) |
37 |
(268 |
) |
2 |
|
||||||||
Net (loss) income attributable to |
|||||||||||||||
(326 |
) |
6 |
(327 |
) |
(58 |
) |
|||||||||
Adjusted EBITDA (c) | 253 |
|
453 |
662 |
|
948 |
|
||||||||
Net cash provided by operating activities | 53 |
|
179 |
154 |
|
280 |
|
||||||||
(Loss) earnings per share attributable to Community | |||||||||||||||
Basic (f) | $ | (2.52 |
) |
$ | 0.04 |
$ | (2.54 |
) |
$ | (0.46 |
) |
||||
Diluted (e), (f) | (2.52 |
) |
0.04 |
(2.54 |
) |
(0.46 |
) |
||||||||
Weighted-average number of shares outstanding (d): | |||||||||||||||
Basic | 129 |
|
127 |
128 |
|
126 |
|
||||||||
Diluted | 129 |
|
131 |
128 |
|
126 |
|
____
For footnotes, see pages 12, 13 and 14.
Condensed Consolidated Statements of Income (a)(b) | |||||||||||||||
(In millions, except per share amounts) | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended |
|||||||||||||||
2022 |
2021 |
||||||||||||||
% of Net | % of Net | ||||||||||||||
Operating | Operating | ||||||||||||||
Amount | Revenues | Amount | Revenues | ||||||||||||
Net operating revenues | $ | 2,934 |
|
100.0 |
|
% |
$ | 3,007 |
|
100.0 |
|
% |
|||
Operating costs and expenses: | |||||||||||||||
Salaries and benefits | 1,295 |
|
44.1 |
|
% |
1,266 |
|
42.1 |
|
% |
|||||
Supplies | 487 |
|
16.6 |
|
% |
500 |
|
16.6 |
|
% |
|||||
Other operating expenses | 830 |
|
28.3 |
|
% |
715 |
|
23.8 |
|
% |
|||||
Lease cost and rent | 78 |
|
2.7 |
|
% |
78 |
|
2.6 |
|
% |
|||||
Pandemic relief funds | (8 |
) |
(0.3 |
) |
% |
(1 |
) |
(0.0 |
) |
% |
|||||
Depreciation and amortization | 133 |
|
4.5 |
|
% |
133 |
|
4.4 |
|
% |
|||||
Impairment and (gain) loss on sale of businesses, net (f) | - |
|
- |
|
% |
2 |
|
0.1 |
|
% |
|||||
Total operating costs and expenses | 2,815 |
|
95.9 |
|
% |
2,693 |
|
89.6 |
|
% |
|||||
Income from operations (f) | 119 |
|
4.1 |
|
% |
314 |
|
10.4 |
|
% |
|||||
Interest expense, net | 218 |
|
7.4 |
|
% |
219 |
|
7.2 |
|
% |
|||||
Loss from early extinguishment of debt | - |
|
- |
|
% |
8 |
|
0.3 |
|
% |
|||||
Equity in earnings of unconsolidated affiliates | (1 |
) |
(0.0 |
) |
% |
(4 |
) |
(0.1 |
) |
% |
|||||
(Loss) income before income taxes | (98 |
) |
(3.3 |
) |
% |
91 |
|
3.0 |
|
% |
|||||
Provision for income taxes | 200 |
|
6.8 |
|
% |
54 |
|
1.8 |
|
% |
|||||
Net (loss) income (f) | (298 |
) |
(10.1 |
) |
% |
37 |
|
1.2 |
|
% |
|||||
Less: Net income attributable to noncontrolling interests | 28 |
|
1.0 |
|
% |
31 |
|
1.0 |
|
% |
|||||
Net (loss) income attributable to |
|||||||||||||||
Inc. stockholders | $ | (326 |
) |
(11.1 |
) |
% |
$ | 6 |
|
0.2 |
|
% |
|||
(Loss) earnings per share attributable to Community | |||||||||||||||
Basic (f) | $ | (2.52 |
) |
$ | 0.04 |
|
|||||||||
Diluted (e), (f) | $ | (2.52 |
) |
$ | 0.04 |
|
|||||||||
Weighted-average number of shares outstanding (d): | |||||||||||||||
Basic | 129 |
|
127 |
|
|||||||||||
Diluted | 129 |
|
131 |
|
____
For footnotes, see pages 12, 13 and 14.
Condensed Consolidated Statements of Loss (a)(b) | |||||||||||||||
(In millions, except per share amounts) | |||||||||||||||
(Unaudited) | |||||||||||||||
Six Months Ended |
|||||||||||||||
2022 |
2021 |
||||||||||||||
% of Net | % of Net | ||||||||||||||
Operating | Operating | ||||||||||||||
Amount | Revenues | Amount | Revenues | ||||||||||||
Net operating revenues | $ | 6,044 |
|
100.0 |
|
% |
$ | 6,020 |
|
100.0 |
|
% |
|||
Operating costs and expenses: | |||||||||||||||
Salaries and benefits | 2,620 |
|
43.4 |
|
% |
2,569 |
|
42.7 |
|
% |
|||||
Supplies | 985 |
|
16.3 |
|
% |
992 |
|
16.5 |
|
% |
|||||
Other operating expenses | 1,683 |
|
27.8 |
|
% |
1,453 |
|
24.1 |
|
% |
|||||
Lease cost and rent | 155 |
|
2.6 |
|
% |
156 |
|
2.6 |
|
% |
|||||
Pandemic relief funds | (55 |
) |
(0.9 |
) |
% |
(83 |
) |
(1.4 |
) |
% |
|||||
Depreciation and amortization | 261 |
|
4.3 |
|
% |
272 |
|
4.5 |
|
% |
|||||
Impairment and (gain) loss on sale of businesses, net (f) | 6 |
|
0.1 |
|
% |
23 |
|
0.4 |
|
% |
|||||
Total operating costs and expenses | 5,655 |
|
93.6 |
|
% |
5,382 |
|
89.4 |
|
% |
|||||
Income from operations (f) | 389 |
|
6.4 |
|
% |
638 |
|
10.6 |
|
% |
|||||
Interest expense, net | 435 |
|
7.2 |
|
% |
449 |
|
7.5 |
|
% |
|||||
Loss from early extinguishment of debt | 5 |
|
- |
|
% |
79 |
|
1.3 |
|
% |
|||||
Equity in earnings of unconsolidated affiliates | (6 |
) |
(0.1 |
) |
% |
(15 |
) |
(0.2 |
) |
% |
|||||
(Loss) income before income taxes | (45 |
) |
(0.7 |
) |
% |
125 |
|
2.0 |
|
% |
|||||
Provision for income taxes | 223 |
|
3.7 |
|
% |
123 |
|
2.0 |
|
% |
|||||
Net (loss) income (f) | (268 |
) |
(4.4 |
) |
% |
2 |
|
0.0 |
|
% |
|||||
Less: Net income attributable to noncontrolling interests | 59 |
|
1.0 |
|
% |
60 |
|
1.0 |
|
% |
|||||
Net loss attributable to |
|||||||||||||||
Inc. stockholders | $ | (327 |
) |
(5.4 |
) |
% |
$ | (58 |
) |
(1.0 |
) |
% |
|||
Loss per share attributable to Community | |||||||||||||||
Basic (f) | $ | (2.54 |
) |
$ | (0.46 |
) |
|||||||||
Diluted (e), (f) | $ | (2.54 |
) |
$ | (0.46 |
) |
|||||||||
Weighted-average number of shares outstanding (d): | |||||||||||||||
Basic | 128 |
|
126 |
|
|||||||||||
Diluted | 128 |
|
126 |
|
____
For footnotes, see pages 12, 13 and 14.
Condensed Consolidated Statements of Comprehensive Loss | ||||||||||||||
(In millions) | ||||||||||||||
(Unaudited) | ||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||
Net (loss) income | $ | (298 |
) |
$ | 37 |
$ | (268 |
) |
$ | 2 |
|
|||
Other comprehensive (loss) income, net of income taxes: | ||||||||||||||
Net change in fair value of available-for-sale debt | ||||||||||||||
securities, net of tax | (6 |
) |
1 |
(14 |
) |
(3 |
) |
|||||||
Amortization and recognition of unrecognized pension cost | ||||||||||||||
components, net of tax | - |
|
- |
- |
|
1 |
|
|||||||
Other comprehensive (loss) income | (6 |
) |
1 |
(14 |
) |
(2 |
) |
|||||||
Comprehensive (loss) income | (304 |
) |
38 |
(282 |
) |
- |
|
|||||||
Less: Comprehensive income attributable to noncontrolling interests | 28 |
|
31 |
59 |
|
60 |
|
|||||||
Comprehensive (loss) income attributable to |
||||||||||||||
$ | (332 |
) |
$ | 7 |
$ | (341 |
) |
$ | (60 |
) |
____
For footnotes, see pages 12, 13 and 14.
Selected Operating Data (a) | |||||||||||||||||||||
(Dollars in millions) | |||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||
Three Months Ended |
|||||||||||||||||||||
Consolidated | Same-Store | ||||||||||||||||||||
|
2022 |
|
2021 |
|
% Change |
|
2022 |
|
2021 |
|
% Change |
||||||||||
Number of hospitals (at end of period) |
|
84 |
|
|
84 |
|
|
83 |
|
|
83 |
|
|||||||||
Licensed beds (at end of period) |
|
13,341 |
|
|
13,320 |
|
|
13,289 |
|
|
13,320 |
|
|||||||||
Beds in service (at end of period) |
|
11,608 |
|
|
11,748 |
|
|
11,556 |
|
|
11,748 |
|
|||||||||
Admissions |
|
107,805 |
|
|
111,543 |
|
-3.4 |
% |
|
107,682 |
|
|
111,543 |
|
-3.5 |
% |
|||||
Adjusted admissions |
|
247,119 |
|
|
248,013 |
|
-0.4 |
% |
|
246,771 |
|
|
248,004 |
|
-0.5 |
% |
|||||
Patient days |
|
498,198 |
|
|
517,289 |
|
|
497,858 |
|
|
517,289 |
|
|||||||||
Average length of stay (days) |
|
4.6 |
|
|
4.6 |
|
|
4.6 |
|
|
4.6 |
|
|||||||||
Occupancy rate (average beds in service) |
|
47.3 |
% |
|
48.4 |
% |
|
47.3 |
% |
|
48.4 |
% |
|||||||||
Net operating revenues | $ |
2,934 |
|
$ |
3,007 |
|
-2.4 |
% |
$ |
2,928 |
|
$ |
3,007 |
|
-2.6 |
% |
|||||
Net inpatient revenues as a % of net operating | |||||||||||||||||||||
revenues |
|
44.9 |
% |
|
46.1 |
% |
|
44.9 |
% |
|
46.0 |
% |
|||||||||
Net outpatient revenues as a % of net operating | |||||||||||||||||||||
revenues |
|
55.1 |
% |
|
53.9 |
% |
|
55.1 |
% |
|
54.0 |
% |
|||||||||
Income from operations (f) | $ |
119 |
|
$ |
314 |
|
-62.1 |
% |
|||||||||||||
Income from operations as a % | |||||||||||||||||||||
of net operating revenues |
|
4.1 |
% |
|
10.4 |
% |
|||||||||||||||
Depreciation and amortization | $ |
133 |
|
$ |
133 |
|
|||||||||||||||
Equity in earnings of unconsolidated affiliates | $ |
(1 |
) |
$ |
(4 |
) |
|||||||||||||||
Net (loss) income attributable to |
|||||||||||||||||||||
$ |
(326 |
) |
$ |
6 |
|
-5533.3 |
% |
||||||||||||||
Net (loss) income attributable to |
|||||||||||||||||||||
operating revenues |
|
-11.1 |
% |
|
0.2 |
% |
|||||||||||||||
Adjusted EBITDA (c) | $ |
253 |
|
$ |
453 |
|
-44.2 |
% |
|||||||||||||
Adjusted EBITDA as a % of net | |||||||||||||||||||||
operating revenues |
|
8.6 |
% |
|
15.1 |
% |
|||||||||||||||
Net cash provided by operating activities | $ |
53 |
|
$ |
179 |
|
-70.4 |
% |
____
For footnotes, see pages 12, 13 and 14.
Selected Operating Data (a) | |||||||||||||||||||||
(Dollars in millions) | |||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||
Six Months Ended |
|||||||||||||||||||||
Consolidated | Same-Store | ||||||||||||||||||||
|
2022 |
|
2021 |
|
% Change |
|
2022 |
|
2021 |
|
% Change |
||||||||||
Number of hospitals (at end of period) |
|
84 |
|
|
84 |
|
|
83 |
|
|
83 |
|
|||||||||
Licensed beds (at end of period) |
|
13,341 |
|
|
13,320 |
|
|
13,289 |
|
|
13,320 |
|
|||||||||
Beds in service (at end of period) |
|
11,608 |
|
|
11,748 |
|
|
11,556 |
|
|
11,748 |
|
|||||||||
Admissions |
|
216,172 |
|
|
221,811 |
|
-2.5 |
% |
|
216,049 |
|
|
220,232 |
|
-1.9 |
% |
|||||
Adjusted admissions |
|
478,926 |
|
|
474,941 |
|
0.8 |
% |
|
478,559 |
|
|
472,600 |
|
1.3 |
% |
|||||
Patient days |
|
1,049,443 |
|
|
1,067,280 |
|
|
1,049,103 |
|
|
1,058,830 |
|
|||||||||
Average length of stay (days) |
|
4.9 |
|
|
4.8 |
|
|
4.9 |
|
|
4.8 |
|
|||||||||
Occupancy rate (average beds in service) |
|
50.1 |
% |
|
49.6 |
% |
|
50.2 |
% |
|
49.8 |
% |
|||||||||
Net operating revenues | $ |
6,044 |
|
$ |
6,020 |
|
0.4 |
% |
$ |
6,036 |
|
$ |
6,002 |
|
0.6 |
% |
|||||
Net inpatient revenues as a % of net operating | |||||||||||||||||||||
revenues |
|
47.2 |
% |
|
48.0 |
% |
|
47.2 |
% |
|
47.8 |
% |
|||||||||
Net outpatient revenues as a % of net operating | |||||||||||||||||||||
revenues |
|
52.8 |
% |
|
52.0 |
% |
|
52.8 |
% |
|
52.2 |
% |
|||||||||
Income from operations (f) | $ |
389 |
|
$ |
638 |
|
-39.0 |
% |
|||||||||||||
Income from operations as a % of net | |||||||||||||||||||||
operating revenues |
|
6.4 |
% |
|
10.6 |
% |
|||||||||||||||
Depreciation and amortization | $ |
261 |
|
$ |
272 |
|
|||||||||||||||
Equity in earnings of unconsolidated affiliates | $ |
(6 |
) |
$ |
(15 |
) |
|||||||||||||||
Net loss attributable to |
|||||||||||||||||||||
$ |
(327 |
) |
$ |
(58 |
) |
-463.8 |
% |
||||||||||||||
Net loss attributable to |
|||||||||||||||||||||
operating revenues |
|
-5.4 |
% |
|
-1.0 |
% |
|||||||||||||||
Adjusted EBITDA (c) | $ |
662 |
|
$ |
948 |
|
-30.2 |
% |
|||||||||||||
Adjusted EBITDA as a % of net | |||||||||||||||||||||
operating revenues |
|
11.0 |
% |
|
15.7 |
% |
|||||||||||||||
Net cash provided by operating activities | $ |
154 |
|
$ |
280 |
|
-45.0 |
% |
|||||||||||||
____
For footnotes, see pages 12, 13 and 14.
Condensed Consolidated Balance Sheets | ||||||||
(In millions, except share data) | ||||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 346 |
|
$ | 507 |
|
||
Patient accounts receivable | 2,001 |
|
2,062 |
|
||||
Supplies | 356 |
|
355 |
|
||||
Prepaid income taxes | 99 |
|
94 |
|
||||
Prepaid expenses and taxes | 263 |
|
192 |
|
||||
Other current assets | 264 |
|
269 |
|
||||
Total current assets | 3,329 |
|
3,479 |
|
||||
Property and equipment | 9,759 |
|
9,757 |
|
||||
Less accumulated depreciation and amortization | (4,220 |
) |
(4,204 |
) |
||||
Property and equipment, net | 5,539 |
|
5,553 |
|
||||
4,224 |
|
4,219 |
|
|||||
Deferred income taxes | 53 |
|
53 |
|
||||
Other assets, net | 1,913 |
|
1,913 |
|
||||
Total assets | $ | 15,058 |
|
$ | 15,217 |
|
||
LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
Current liabilities | ||||||||
Current maturities of long-term debt | $ | 32 |
|
$ | 31 |
|
||
Current operating lease liabilities | 153 |
|
147 |
|
||||
Accounts payable | 832 |
|
830 |
|
||||
Accrued liabilities: | ||||||||
Employee compensation | 624 |
|
655 |
|
||||
Accrued interest | 221 |
|
225 |
|
||||
Other | 433 |
|
476 |
|
||||
Total current liabilities | 2,295 |
|
2,364 |
|
||||
Long-term debt (g) | 12,183 |
|
12,109 |
|
||||
Deferred income taxes | 410 |
|
192 |
|
||||
Long-term operating lease liabilities | 569 |
|
535 |
|
||||
Other long-term liabilities | 759 |
|
827 |
|
||||
Total liabilities | 16,216 |
|
16,027 |
|
||||
Redeemable noncontrolling interests in equity of consolidated subsidiaries | 498 |
|
480 |
|
||||
STOCKHOLDERS’ DEFICIT | ||||||||
Preferred stock, |
- |
|
- |
|
||||
Common stock, |
||||||||
shares issued and outstanding at |
||||||||
issued and outstanding at |
1 |
|
1 |
|
||||
Additional paid-in capital | 2,090 |
|
2,118 |
|
||||
Accumulated other comprehensive loss | (27 |
) |
(14 |
) |
||||
Accumulated deficit | (3,804 |
) |
(3,477 |
) |
||||
(1,740 |
) |
(1,372 |
) |
|||||
Noncontrolling interests in equity of consolidated subsidiaries | 84 |
|
82 |
|
||||
Total stockholders’ deficit | (1,656 |
) |
(1,290 |
) |
||||
Total liabilities and stockholders’ deficit | $ | 15,058 |
|
$ | 15,217 |
|
____
For footnotes, see pages 12, 13 and 14.
Condensed Consolidated Statements of Cash Flows | |||||||
(In millions) | |||||||
(Unaudited) | |||||||
Six Months Ended |
|||||||
2022 |
2021 |
||||||
Cash flows from operating activities | |||||||
Net (loss) income | $ | (268 |
) |
$ | 2 |
|
|
Adjustments to reconcile net (loss) income to net cash provided by | |||||||
operating activities: | |||||||
Depreciation and amortization | 261 |
|
272 |
|
|||
Deferred income taxes | 221 |
|
118 |
|
|||
Stock-based compensation expense | 8 |
|
13 |
|
|||
Impairment and (gain) loss on sale of businesses, net (f) | 6 |
|
23 |
|
|||
Loss from early extinguishment of debt | 5 |
|
79 |
|
|||
Other non-cash expenses, net | 95 |
|
(3 |
) |
|||
Changes in operating assets and liabilities, net of effects of | |||||||
acquisitions and divestitures: | |||||||
Patient accounts receivable | 61 |
|
(32 |
) |
|||
Supplies, prepaid expenses and other current assets | (72 |
) |
31 |
|
|||
Repayment/derecognition of Medicare accelerated payments | - |
|
(134 |
) |
|||
Accounts payable, accrued liabilities and income taxes | (63 |
) |
(2 |
) |
|||
Other | (100 |
) |
(87 |
) |
|||
Net cash provided by operating activities | 154 |
|
280 |
|
|||
Cash flows from investing activities | |||||||
Acquisitions of facilities and other related businesses | (4 |
) |
(4 |
) |
|||
Purchases of property and equipment | (191 |
) |
(212 |
) |
|||
Proceeds from disposition of hospitals and other ancillary operations | 3 |
|
7 |
|
|||
Proceeds from sale of property and equipment | 7 |
|
3 |
|
|||
Purchases of available-for-sale debt securities and equity securities | (55 |
) |
(63 |
) |
|||
Proceeds from sales of available-for-sale debt securities and equity securities | 41 |
|
48 |
|
|||
Purchases of investments in unconsolidated affiliates | (8 |
) |
(2 |
) |
|||
Increase in other investments | (30 |
) |
(32 |
) |
|||
Net cash used in investing activities | (237 |
) |
(255 |
) |
|||
Cash flows from financing activities | |||||||
Repurchase of restricted stock shares for payroll tax withholding requirements | (8 |
) |
(5 |
) |
|||
Deferred financing costs and other debt-related costs | (73 |
) |
(310 |
) |
|||
Proceeds from noncontrolling investors in joint ventures | 1 |
|
- |
|
|||
Redemption of noncontrolling investments in joint ventures | (1 |
) |
(3 |
) |
|||
Distributions to noncontrolling investors in joint ventures | (73 |
) |
(66 |
) |
|||
Other borrowings | 34 |
|
19 |
|
|||
Issuance of long-term debt | 1,535 |
|
4,310 |
|
|||
Repayments of long-term indebtedness | (1,493 |
) |
(4,396 |
) |
|||
Net cash used in financing activities | (78 |
) |
(451 |
) |
|||
Net change in cash and cash equivalents | (161 |
) |
(426 |
) |
|||
Cash and cash equivalents at beginning of period | 507 |
|
1,676 |
|
|||
Cash and cash equivalents at end of period | $ | 346 |
|
$ | 1,250 |
|
|
____
For footnotes, see pages 12, 13 and 14.
Footnotes to Financial Highlights, Financial Statements and Selected Operating Data
(a) |
Both financial and statistical results include the operating results of divested or closed businesses for the periods prior to the consummation of the respective divestiture or closing. Same-store operating results and statistical information exclude businesses divested or closed in 2021 and one hospital opened in 2022. There were no discontinued operations reported for 2022 and 2021. |
|
|
||
(b) |
The following table provides information needed to calculate loss per share, which is adjusted for income attributable to noncontrolling interests (in millions): |
Three Months Ended | Six Months Ended | ||||||||||||||||
2022 |
2021 |
2022 |
2021 |
||||||||||||||
Net (loss) income attributable to |
|||||||||||||||||
Inc. stockholders: | |||||||||||||||||
Net (loss) income | $ | (298 |
) |
$ | 37 |
$ | (268 |
) |
$ | 2 |
|
||||||
Less: Income attributable to noncontrolling interests, net of taxes | 28 |
|
31 |
59 |
|
60 |
|
||||||||||
Net (loss) income attributable to |
|||||||||||||||||
Inc. stockholders — basic and diluted | $ | (326 |
) |
$ | 6 |
$ | (327 |
) |
$ | (58 |
) |
(c) |
EBITDA is a non-GAAP financial measure which consists of net (loss) income attributable to |
|
Adjusted EBITDA is not a measurement of financial performance under |
||
The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net (loss) income attributable to |
Three Months Ended | Six Months Ended | ||||||||||||||||
2022 |
2021 |
2022 |
2021 |
||||||||||||||
Net (loss) income attributable to |
|||||||||||||||||
$ | (326 |
) |
$ | 6 |
$ | (327 |
) |
$ | (58 |
) |
|||||||
Adjustments: | |||||||||||||||||
Provision for income taxes | 200 |
|
54 |
223 |
|
123 |
|
||||||||||
Depreciation and amortization | 133 |
|
133 |
261 |
|
272 |
|
||||||||||
Net income attributable to noncontrolling interests | 28 |
|
31 |
59 |
|
60 |
|
||||||||||
Interest expense, net | 218 |
|
219 |
435 |
|
449 |
|
||||||||||
Loss from early extinguishment of debt | - |
|
8 |
5 |
|
79 |
|
||||||||||
Impairment and (gain) loss on sale of businesses, net | - |
|
2 |
6 |
|
23 |
|
||||||||||
Adjusted EBITDA | $ | 253 |
|
$ | 453 |
$ | 662 |
|
$ | 948 |
|
(d) |
The following table sets forth components reconciling the basic weighted-average number of shares to the diluted weighted-average number of shares (in millions): |
Three Months Ended | Six Months Ended | |||||||||
2022 |
2021 |
2022 |
2021 |
|||||||
Weighted-average number of shares outstanding - basic | 129 |
127 |
128 |
126 |
||||||
Add effect of dilutive securities: | ||||||||||
Stock awards and options | - |
4 |
- |
- |
||||||
Weighted-average number of shares outstanding - diluted | 129 |
131 |
128 |
126 |
The Company generated a net loss attributable to |
||
(e) |
The following supplemental table reconciles net (loss) income attributable to |
Three Months Ended | Six Months Ended | |||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||
Net (loss) income per share (diluted), as reported | $ |
(2.52 |
) |
$ |
0.04 |
$ |
(2.54 |
) |
$ |
(0.46 |
) |
|||
Adjustments: | ||||||||||||||
Loss from early extinguishment of debt |
|
- |
|
|
0.18 |
|
0.11 |
|
|
0.92 |
|
|||
Impairment and (gain) loss on sale of businesses, net |
|
- |
|
|
0.01 |
|
0.04 |
|
|
0.14 |
|
|||
Net (loss) income per share (diluted), excluding adjustments | $ |
(2.52 |
) |
$ |
0.23 |
$ |
(2.40 |
) |
$ |
0.60 |
(f) |
Both income from operations and net (loss) income included a net non-cash expense of |
|
|
||
(g) |
The maximum aggregate principal amount under the ABL Facility is |
Regulation FD Disclosure
Set forth below is selected information concerning the Company’s projected consolidated operating results for the year ending
The following is provided as guidance to analysts and investors:
2022 |
|||||||||
Net operating revenues (in millions) | $ | 12,200 |
to | $ | 12,500 |
||||
Adjusted EBITDA (in millions) | $ | 1,300 |
to | $ | 1,400 |
||||
Net loss per share - diluted | $ | (2.55) |
to | $ | (1.65) |
||||
Weighted-average diluted shares (in millions) | 128.0 |
to | 129.0 |
The following assumptions were used in developing the 2022 guidance provided above:
-
The Company’s projections exclude the following:
- Effect of debt refinancing activities, including gains and losses from early extinguishment of debt;
- Impairment of goodwill and long-lived assets;
- Previously recorded pandemic relief funds and the potential recognition of additional pandemic relief funds;
- The impact of any potential future divestitures;
- Gains or losses from the sales of businesses;
- Employee termination benefits and restructuring costs;
- Resolution of government investigations or other significant legal settlements;
- Costs incurred in connection with divestitures; and
- Other significant gains or losses that neither relate to the ordinary course of business nor reflect the Company’s underlying business performance.
Other assumptions used in the above guidance:
-
Expressed as a percentage of net operating revenues, depreciation and amortization of approximately
4.2% for 2022. Additionally, this is a fixed cost and the percentages may vary based on changes in net operating revenues. Such amounts exclude the possible impact of any future hospital fixed asset impairments.
-
Interest expense is estimated to be between
and$855 million while cash paid for interest, which excludes the amortization of deferred financing costs, is expected to be$875 million to$820 million . Total fixed rate debt is expected to average approximately$840 million 100% of total debt during 2022.
-
Expressed as a percentage of net operating revenues, net income attributable to noncontrolling interests of approximately
0.9% to1.0% for 2022.
-
Expressed as a percentage of net operating revenues, provision for income taxes of approximately
0.9% to1.0% for 2022.
A reconciliation of the Company’s projected 2022 Adjusted EBITDA, a forward-looking non-GAAP financial measure, to the Company’s projected net loss attributable to
Year Ending | |||||||
Low | High | ||||||
Net loss attributable to |
|||||||
stockholders (1) | $ | (326 |
) |
$ | (213 |
) |
|
Adjustments: | |||||||
Depreciation and amortization | 530 |
|
515 |
|
|||
Interest expense, net | 875 |
|
855 |
|
|||
Provision for income taxes | 111 |
|
123 |
|
|||
Net income attributable to noncontrolling interests | 110 |
|
120 |
|
|||
Adjusted EBITDA (1) | $ | 1,300 |
|
$ | 1,400 |
|
(1) |
The Company does not include in this reconciliation the impact of certain items not included in the Company’s forecast set forth above that would be included in a reconciliation of historical net (loss) income attributable to |
- Capital expenditures are projected as follows (in millions):
2022 |
|||||
Guidance | |||||
Total |
|
to |
|
- Net cash provided by operating activities are projected as follows (in millions):
2022 |
|||||
Guidance | |||||
Total |
|
to |
|
- Diluted weighted-average shares outstanding are projected to be approximately 128 million to 129 million for 2022.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this press release other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions, are forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company’s expected results to differ materially from those expressed in this press release.
These factors include, among other things:
- developments related to COVID-19, including, without limitation, related to the length and severity of the pandemic; the volume of canceled or rescheduled procedures; and the spread of potentially more contagious and/or virulent forms of the virus, including variants of the virus for which currently available vaccines, treatments and tests may not be effective or authorized;
- uncertainty regarding the magnitude and timing of any future payments or benefits we may receive or realize under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), the Consolidated Appropriations Act, 2021 (the “CAA”), the American Rescue Plan Act of 2021 (the “ARPA”) and any other future stimulus measures related to COVID-19;
- general economic and business conditions, both nationally and in the regions in which we operate, including inflationary pressures that have significantly increased and may continue to significantly increase our expenses, the extremely competitive labor market and labor shortages, and supply chain shortages and disruptions, as well as the current and/or potential future adverse impact of such economic conditions and other factors on our net operating revenues (including our service mix, revenue mix, payor mix and/or patient volumes) and our ability to collect outstanding receivables;
- the impact of current or future federal and state health reform initiatives, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Affordable Care Act”), and the potential for changes to the Affordable Care Act, its implementation or its interpretation (including through executive orders and court challenges);
- the extent to and manner in which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through legislation, regulation or otherwise;
- the future and long-term viability of health insurance exchanges and potential changes to the beneficiary enrollment process;
- risks associated with our substantial indebtedness, leverage and debt service obligations, including our ability to refinance such indebtedness on acceptable terms or to incur additional indebtedness, and our ability to remain in compliance with debt covenants;
- demographic changes;
- changes in, or the failure to comply with, federal, state or local laws or governmental regulations affecting our business, including any such laws or governmental regulations which are adopted in connection with the COVID-19 pandemic;
- potential adverse impact of known and unknown legal, regulatory and governmental proceedings and other loss contingencies, including governmental investigations and audits, and federal and state false claims act litigation;
- our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further affected by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers;
- changes in, or the failure to comply with, contract terms with payors and changes in reimbursement policies or rates paid by federal or state healthcare programs or commercial payors;
- any security breaches, cyber-attacks, loss of data, other cybersecurity threats or incidents, and any actual or perceived failures to comply with legal requirements governing the privacy and security of health information or other regulated, sensitive or confidential information, or legal requirements regarding data privacy or data protection;
- any potential impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets;
- changes in inpatient or outpatient Medicare and Medicaid payment levels and methodologies;
- the effects related to the implementation of the sequestration spending reductions pursuant to both the Budget Control Act of 2011 and the Pay-As-You-Go Act of 2010 and the potential for future deficit reduction legislation;
- increases in the amount and risk of collectability of patient accounts receivable, including decreases in collectability which may result from, among other things, self-pay growth and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles;
- the efforts of insurers, healthcare providers, large employer groups and others to contain healthcare costs, including the trend toward value-based purchasing;
- the impact of competitive labor market conditions and the shortage of experienced nurses, including in connection with our ability to hire and retain qualified nurses, physicians, other medical personnel and key management, and increased labor expenses as a result of such competitive labor market conditions, inflation and competition for such positions;
- any failure to obtain medical supplies or pharmaceuticals at favorable prices;
- liabilities and other claims asserted against us, including self-insured malpractice claims;
- competition;
- trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals or via telehealth;
- changes in medical or other technology;
-
changes in
U.S. GAAP; - the availability and terms of capital to fund any additional acquisitions or replacement facilities or other capital expenditures;
- our ability to successfully make acquisitions or complete divestitures, our ability to complete any such acquisitions or divestitures on desired terms or at all, the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures;
- the impact that changes in our relationships with joint venture or syndication partners could have on effectively operating our hospitals or ancillary services or in advancing strategic opportunities;
- our ability to successfully integrate any acquired hospitals and/or outpatient facilities, or to recognize expected synergies from acquisitions;
- the impact of seasonal severe weather conditions and climate change, as well as the timing and amount of insurance recoveries in relation to severe weather events;
- our ability to obtain adequate levels of insurance, including cyber, general liability, professional liability, and directors and officers liability insurance;
- timeliness of reimbursement payments received under government programs;
- effects related to pandemics, epidemics, or outbreaks of infectious diseases, including the coronavirus causing the disease known as COVID-19;
- any failure to comply with our obligations under license or technology agreements;
- challenging economic conditions in non-urban communities in which we operate;
- any developments with respect to the final auditing and reporting requirements of, or other adverse developments with respect to, the Corporate Integrity Agreement to which we are subject;
- the concentration of our revenue in a small number of states;
- our ability to realize anticipated cost savings and other benefits from our current strategic and operational cost savings initiatives;
- any changes in or interpretations of income tax laws and regulations; and
-
the risk factors set forth in our Annual Report on Form 10-K for the year ended
December 31, 2021 , filed with theSecurities and Exchange Commission onFebruary 17, 2022 , and other public filings with theSecurities and Exchange Commission .
The consolidated operating results for the three and six months ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005827/en/
Investor Contact:
President and
Chief Financial Officer
(615) 465-7000
Source:
FAQ
What were Community Health Systems' Q2 2022 net operating revenues?
What was the net loss per share for Community Health Systems in Q2 2022?
How did adjusted EBITDA change for Community Health Systems in Q2 2022?
What challenges did Community Health Systems face in Q2 2022?